Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

COMPLETED

NCT04133909

PHASE3

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study designed to confirm the benefits of mepolizumab treatment on moderate or severe exacerbations in chronic obstructive pulmonary disease (COPD) participants given as an add on to their optimized maintenance COPD therapy. The maximum duration of participant participation is approximately 109 weeks, consisting of 2 screening visits (up to 3 weeks), a run-in period (up to 2 weeks), and an intervention period of at least 52 weeks and up to 104 weeks. 800 participants will be randomized in a 1:1 ratio to receive mepolizumab 100 milligrams (mg) or placebo every 4 weeks for at least 13 doses (52 weeks treatment period) up to a maximum of 26 doses (104 weeks treatment period). The number of randomized participants may increase up to approximately 1400.

Official title: A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)

Key Details

Gender

All

Age Range

40 Years - Any

Study Type

INTERVENTIONAL

Enrollment

806

Start Date

2019-10-30

Completion Date

2024-08-08

Last Updated

2026-08-21

Healthy Volunteers

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

BIOLOGICAL

Mepolizumab

Mepolizumab was a sterile liquid formulation. It was administered as a subcutaneous injection (100 milligrams per milliliter \[mg/mL\]) delivered once every 4 weeks using a pre-filled safety syringe.

DRUG

Placebo

Placebo was a 0.9% sodium chloride solution. It was administered as a subcutaneous injection delivered once every 4 weeks using a pre-filled safety syringe.

Inclusion Criteria: * Participant must be at least 40 years of age at Screening Visit 1. * Participants with a peripheral blood eosinophil count of \>=300 cells per microliter (μL) from the hematology sample collected at Screening Visit 0 AND a documented historical blood eosinophil count of \>=150 cells per μL in the 12 months prior to Screening Visit 0 that meets the following: It must have been measured between 12 months and 1 month prior to Screening Visit 0, and it must not have been measured within 14 days of a COPD exacerbation. Participants with no documented historical blood eosinophil count of \>=150 cells per µL must meet this threshold at the Screening Visit 1 assessment. * Participants with a clinically documented history of COPD for at least 1 year in accordance with the definition by the American Thoracic Society or European Respiratory Society. * Participants must present with a measured pre- and post-salbutamol Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio of \<0.70 at Screening Visit 1 to confirm the diagnosis of COPD and with a measured post-salbutamol FEV1\>20% and \<=80% of predicted normal values calculated using NHANES III reference equations at Screening Visit 1. * Participants must have a well-documented history (for example, medical record verification) in the 12 months prior to Screening Visit 1 of two or more moderate COPD exacerbations that were treated with systemic corticosteroids (intramuscular \[IM\], intravenous, or oral) with or without antibiotics or at least one severe COPD exacerbation requiring hospitalization. * Participants must have a well-documented requirement for optimized standard of care background therapy that includes inhaled corticosteroids (ICS) plus 2 additional COPD medications (ICS-based triple therapy) for the 12 months prior to Screening Visit 1 and meets the following criteria: immediately prior to Screening Visit 1, minimum of 3 months of use of an 1) inhaled corticosteroid at a dose \>=500 microgram (mcg) per day fluticasone propionate dose equivalent plus 2) Long acting beta2-agonist (LABA) and 3) Long acting muscarinic antagonist (LAMA) unless documentation of safety or intolerance issues related to LABA or LAMA. For participants who are not continually maintained on ICS plus LABA plus LAMA for the entire 12 months prior to Visit 1 use of the following is allowed (but not in the 3 months immediately prior to Visit 1); inhaled corticosteroid at a dose \>=500 mcg per day fluticasone propionate dose equivalent plus inhaled LABA or inhaled LAMA and Phosphodiesterase-4-inhibitors, methylxanthines, or scheduled daily use of short acting beta2-agonist (SABA) and/or short acting muscarinic antagonist (SAMA). * Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Screening (Visit 1) calculated as (number of pack years = \[number of cigarettes per day/20\] multiplied by number of years smoked \[For example, 20 cigarettes per day for 10 years or 10 cigarettes per day for 20 years\]). * Contraceptive use for female participant should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: She is not a woman of childbearing potential (WOCBP) or she is a WOCBP and using a contraceptive method that is highly effective, with a failure rate of \<1%, during the intervention period and for at least 16 weeks after the last dose of study intervention. The principal investigator (PI) should evaluate the effectiveness of the contraceptive method in relation to the first dose of study intervention. * A WOCBP must have a negative highly sensitive pregnancy urine test within 24 hours before the first dose of study intervention. If a urine test cannot be confirmed as negative (For example, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. * Participants capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Participants must meet following randomization inclusion criteria at Visit 2 to be randomized and commence the study intervention period: a) Participants that do not have documented historical blood eosinophil count of ≥150 cells/μL prior to Screening Visit must meet this threshold based on the Screening Visit 1 assessment, b) Participants must have eosinophil count of ≥300 cells/μL from the hematology sample collected at Screening Visit 0, c) Compliance with completion of the e-diary defined as completion of all questions on 5 or more days out of the 7 days immediately preceding Visit 2. Exclusion Criteria: * Participants with a past history or concurrent diagnosis of asthma are excluded regardless of whether they have active or inactive disease. * The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease. Participants with alpha1-antitrypsin deficiency as the underlying cause of COPD are excluded. Also, excluded are participants with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases. * Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1. * Participants with lung volume reduction surgery within the 12 months prior to Screening Visit 1. * Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1. Participants who are in the maintenance phase of a pulmonary rehabilitation program are not excluded. * Participants receiving treatment with oxygen more than 2 liter (L) per minute at rest over 24 hours. For participants receiving oxygen treatment, participants should demonstrate an oxyhemoglobin saturation greater than or equal to 89% while breathing supplemental oxygen. * Participants with a QT interval, from the electrocardiogram (ECG) conducted at Screening Visit 1, corrected with Fridericia's formula (QTcF) \>450 millisecond (msec) (or QTcF \>480 msec in participants with bundle branch block). Fridericia's formula must be used to determine eligibility and discontinuation for an individual participant. Participants are excluded if an abnormal ECG finding from the 12-lead ECG conducted at Screening Visit 1 is considered to be clinically significant and would impact the participant's participation during the study, based on the evaluation of the Investigator. * Participants with any of the following would be excluded: myocardial infarction or unstable angina in the 6 months prior to Screening Visit 1; unstable or life threatening cardiac arrhythmia requiring intervention in the 3 months prior to Screening Visit 1; New York Heart Association (NYHA) Class IV Heart failure. * Participants with (historical or) current evidence of clinically significant, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or which could affect the efficacy or safety analysis if the disease/condition exacerbated during the study. * Participants with other conditions that could lead to elevated eosinophils such as Hypereosinophilic syndromes including Eosinophilic Granulomatosis with Polyangiitis (EGPA), also known as Churg-Strauss Syndrome, or Eosinophilic Esophagitis. * Participants with a known, pre-existing parasitic infestation within 6 months prior to Screening Visit 1. * A current malignancy or previous history of cancer in remission for less than 12 months prior to Screening Visit 1 (participants that had localized carcinoma of the skin or cervix which was resected for cure will not be excluded). * Participants with a known immunodeficiency (For example, human immunodeficiency virus \[HIV\]), other than that explained by the use of corticosteroids taken for COPD. * Participants with cirrhosis or current unstable liver disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice. Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome, asymptomatic gallstones, and chronic stable hepatitis B or C -e.g., presence of hepatitis B surface antigen \[HbsAg\] or positive hepatitis C antibody test result) is acceptable if the participant otherwise meets entry criteria. * Participants who have received interventional product in previous mepolizumab studies are excluded. * Participants who have received any monoclonal antibody within 5 half-lives of Screening Visit 1. * Participants who have received an investigational drug within 30 days of Visit 1, or within 5 drug half-lives of the investigational drug, whichever is longer (this also includes investigational formulations of a marketed product). * Participants who have received short term use of oral corticosteroids within 30 days of Visit 1. * Participants with a known allergy or sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates participation in the study or intolerance to another monoclonal antibody or biologic including history of anaphylaxis to another biologic. * Participants at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits. * Participants with conditions that will limit the validity of informed consent to participate in the study, for example, uncontrolled psychiatric disease or intellectual deficiency. * Participants with a known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1. * Participant is an Investigator, sub-Investigator, study coordinator, employee of a participating Investigator or study site, or immediate family member of the aforementioned that is involved in this study. * Participants with a current active COVID-19 infection, either laboratory confirmed or according to the investigator's medical judgement and who are known to be in contact with active COVID-19 positive individuals within the past 14 days. * Participant will not be randomized if they meet any of the following randomization exclusion criteria at Visit 2: a) Participants who have pneumonia, exacerbation, lower respiratory infection during the Run-in period. b) Evidence of clinically significant abnormality in the hematological or biochemical screen at Visit 1, as judged by the Investigator. c) Participants who meet the following based on results from sample taken at Screening Visit 1: Alanine aminotransferase (ALT) \>2x upper limit of normal (ULN), bilirubin \>1.5 x ULN (isolated bilirubin \>1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%), cirrhosis or current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice. d) Participants who are pregnant or breastfeeding. Participants should not be randomized if they plan to become pregnant during the time of study participation. e) Participants that had an active COVID-19 infection during the Run-in period, either laboratory confirmed or according to the investigator's medical judgment or known to be in contact with active COVID-19 positive individuals within the past 14 days. f) Participants with a QT interval, from the ECG conducted at Visit 2, corrected with Fridericia's formula (QTcF) \>450 msec (or QTcF \>480 msec in participants with bundle branch block).

Locations (339)

GSK Investigational Site

Birmingham, Alabama, United States

GSK Investigational Site

Dothan, Alabama, United States

GSK Investigational Site

Huntsville, Alabama, United States

GSK Investigational Site

Jasper, Alabama, United States

GSK Investigational Site

Chandler, Arizona, United States

GSK Investigational Site

Chandler, Arizona, United States

GSK Investigational Site

Gilbert, Arizona, United States

GSK Investigational Site

Mesa, Arizona, United States

GSK Investigational Site

Phoenix, Arizona, United States

GSK Investigational Site

Phoenix, Arizona, United States

GSK Investigational Site

Phoenix, Arizona, United States

GSK Investigational Site

Tucson, Arizona, United States

GSK Investigational Site

Conway, Arkansas, United States

GSK Investigational Site

Alpine, California, United States

GSK Investigational Site

Cerritos, California, United States

GSK Investigational Site

Newport Beach, California, United States

GSK Investigational Site

San Diego, California, United States

GSK Investigational Site

Torrance, California, United States

GSK Investigational Site

Vista, California, United States

GSK Investigational Site

Colorado Springs, Colorado, United States

GSK Investigational Site

Boynton Beach, Florida, United States

GSK Investigational Site

Clearwater, Florida, United States

GSK Investigational Site

Daytona Beach, Florida, United States

GSK Investigational Site

Doral, Florida, United States

GSK Investigational Site

Hialeah, Florida, United States

GSK Investigational Site

Homestead, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami Lakes, Florida, United States

GSK Investigational Site

Miami Lakes, Florida, United States

GSK Investigational Site

Orlando, Florida, United States

GSK Investigational Site

Pinellas Park, Florida, United States

GSK Investigational Site

Plantation, Florida, United States

GSK Investigational Site

Port Orange, Florida, United States

GSK Investigational Site

St. Petersburg, Florida, United States

GSK Investigational Site

Adairsville, Georgia, United States

GSK Investigational Site

Johns Creek, Georgia, United States

GSK Investigational Site

Lawrenceville, Georgia, United States

GSK Investigational Site

Woodstock, Georgia, United States

GSK Investigational Site

Chicago, Illinois, United States

GSK Investigational Site

Evansville, Indiana, United States

GSK Investigational Site

Valparaiso, Indiana, United States

GSK Investigational Site

Lexington, Kentucky, United States

GSK Investigational Site

Baltimore, Maryland, United States

GSK Investigational Site

Columbia, Maryland, United States

GSK Investigational Site

Lathrup Village, Michigan, United States

GSK Investigational Site

St Louis, Missouri, United States

GSK Investigational Site

Las Vegas, Nevada, United States

GSK Investigational Site

Toms River, New Jersey, United States

GSK Investigational Site

The Bronx, New York, United States

GSK Investigational Site

Charlotte, North Carolina, United States

GSK Investigational Site

Gastonia, North Carolina, United States

GSK Investigational Site

Greenville, North Carolina, United States

GSK Investigational Site

Hickory, North Carolina, United States

GSK Investigational Site

Shelby, North Carolina, United States

GSK Investigational Site

Wilmington, North Carolina, United States

GSK Investigational Site

Winston-Salem, North Carolina, United States

GSK Investigational Site

Cincinnati, Ohio, United States

GSK Investigational Site

Columbus, Ohio, United States

GSK Investigational Site

Columbus, Ohio, United States

GSK Investigational Site

Kettering, Ohio, United States

GSK Investigational Site

Norman, Oklahoma, United States

GSK Investigational Site

Oklahoma City, Oklahoma, United States

GSK Investigational Site

Oregon City, Oregon, United States

GSK Investigational Site

Altoona, Pennsylvania, United States

GSK Investigational Site

Philadelphia, Pennsylvania, United States

GSK Investigational Site

Anderson, South Carolina, United States

GSK Investigational Site

Charleston, South Carolina, United States

GSK Investigational Site

Clinton, South Carolina, United States

GSK Investigational Site

Fort Mill, South Carolina, United States

GSK Investigational Site

Greenville, South Carolina, United States

GSK Investigational Site

Rock Hill, South Carolina, United States

GSK Investigational Site

Spartanburg, South Carolina, United States

GSK Investigational Site

Knoxville, Tennessee, United States

GSK Investigational Site

Corsicana, Texas, United States

GSK Investigational Site

Houston, Texas, United States

GSK Investigational Site

Houston, Texas, United States

GSK Investigational Site

McKinney, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

Sherman, Texas, United States

GSK Investigational Site

Webster, Texas, United States

GSK Investigational Site

Rutland, Vermont, United States

GSK Investigational Site

Berazategui Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Ciudad AutOnoma de Buenos Aire, Argentina

GSK Investigational Site

Ciudad Autonoma de Bueno, Argentina

GSK Investigational Site

Ciudad Autonoma de Bueno, Argentina

GSK Investigational Site

Córdoba, Argentina

GSK Investigational Site

La Plata, Argentina

GSK Investigational Site

Lobos, Argentina

GSK Investigational Site

Mar del Plata, Argentina

GSK Investigational Site

Mar del Plata, Argentina

GSK Investigational Site

Mendoza, Argentina

GSK Investigational Site

Mendoza, Argentina

GSK Investigational Site

Quilmes, Argentina

GSK Investigational Site

Rosario, Argentina

GSK Investigational Site

Rosario, Argentina

GSK Investigational Site

Rosario Provincia de Santa FE, Argentina

GSK Investigational Site

San Miguel de Tucumán, Argentina

GSK Investigational Site

San Miguel de Tucumán, Argentina

GSK Investigational Site

San Rafael, Argentina

GSK Investigational Site

Coffs Harbour, New South Wales, Australia

GSK Investigational Site

New Lambton, New South Wales, Australia

GSK Investigational Site

Sydney, New South Wales, Australia

GSK Investigational Site

Kent Town, South Australia, Australia

GSK Investigational Site

Frankston, Victoria, Australia

GSK Investigational Site

Jambes, Belgium

GSK Investigational Site

Liège, Belgium

GSK Investigational Site

Yvoir, Belgium

GSK Investigational Site

Porto Alegre, Brazil

GSK Investigational Site

Porto Alegre, Brazil

GSK Investigational Site

Porto Alegre, Brazil

GSK Investigational Site

São Paulo, Brazil

GSK Investigational Site

Vancouver, British Columbia, Canada

GSK Investigational Site

Truro, Nova Scotia, Canada

GSK Investigational Site

Ajax, Ontario, Canada

GSK Investigational Site

Sarnia, Ontario, Canada

GSK Investigational Site

Windsor, Ontario, Canada

GSK Investigational Site

Saint-Charles-Borromée, Quebec, Canada

GSK Investigational Site

Baotou, China

GSK Investigational Site

Beijing, China

GSK Investigational Site

Beijing, China

GSK Investigational Site

Beijing, China

GSK Investigational Site

Changchun, China

GSK Investigational Site

Changchun, China

GSK Investigational Site

Changsha, China

GSK Investigational Site

Changsha, China

GSK Investigational Site

Changsha, China

GSK Investigational Site

Changsha, China

GSK Investigational Site

Guangzhou, China

GSK Investigational Site

Guangzhou, China

GSK Investigational Site

Guangzhou, China

GSK Investigational Site

Haikou, China

GSK Investigational Site

Hangzhou, China

GSK Investigational Site

Hangzhou, China

GSK Investigational Site

Hohehot, China

GSK Investigational Site

Jiaxing, China

GSK Investigational Site

Jinan, China

GSK Investigational Site

Nanchang, China

GSK Investigational Site

Nanchang, China

GSK Investigational Site

Nanchang, China

GSK Investigational Site

Nanjing, China

GSK Investigational Site

Nanjing, China

GSK Investigational Site

Nanning, China

GSK Investigational Site

Qingdao, China

GSK Investigational Site

Shanghai, China

GSK Investigational Site

Shanghai, China

GSK Investigational Site

Shanghai, China

GSK Investigational Site

Shanghai, China

GSK Investigational Site

Taiyuan, China

GSK Investigational Site

Taizhou, China

GSK Investigational Site

Ürümqi, China

GSK Investigational Site

Wuhan, China

GSK Investigational Site

Wuxi, China

GSK Investigational Site

Xiamen, China

GSK Investigational Site

Xining, China

GSK Investigational Site

Xinxiang, China

GSK Investigational Site

Zhuhai, China

GSK Investigational Site

Zigong, China

GSK Investigational Site

Aalborg, Denmark

GSK Investigational Site

Hvidovre, Denmark

GSK Investigational Site

Kbenhavn N, Denmark

GSK Investigational Site

Koebenhavn NV, Denmark

GSK Investigational Site

Odense C, Denmark

GSK Investigational Site

Roskilde, Denmark

GSK Investigational Site

Vejle, Denmark

GSK Investigational Site

Tallinn, Estonia

GSK Investigational Site

Brest, France

GSK Investigational Site

Cholet, France

GSK Investigational Site

Epagny Metz-Tessy, France

GSK Investigational Site

Le Mans, France

GSK Investigational Site

Lyon, France

GSK Investigational Site

Montpellier, France

GSK Investigational Site

Mulhouse, France

GSK Investigational Site

Berlin, Germany

GSK Investigational Site

Berlin, Germany

GSK Investigational Site

Berlin, Germany

GSK Investigational Site

Berlin, Germany

GSK Investigational Site

Berlin, Germany

GSK Investigational Site

Berlin, Germany

GSK Investigational Site

Berlin, Germany

GSK Investigational Site

Cottbus, Germany

GSK Investigational Site

Frankfurt, Germany

GSK Investigational Site

Frankfurt, Germany

GSK Investigational Site

Frankfurt, Germany

GSK Investigational Site

Geesthacht, Germany

GSK Investigational Site

Gelsenkirchen, Germany

GSK Investigational Site

Halle, Germany

GSK Investigational Site

Immenhausen, Germany

GSK Investigational Site

Koblenz, Germany

GSK Investigational Site

Leipzig, Germany

GSK Investigational Site

Leipzig, Germany

GSK Investigational Site

Leipzig, Germany

GSK Investigational Site

Leipzig, Germany

GSK Investigational Site

Lübeck, Germany

GSK Investigational Site

Mainz, Germany

GSK Investigational Site

Neu-Isenburg, Germany

GSK Investigational Site

Peine, Germany

GSK Investigational Site

Rheine, Germany

GSK Investigational Site

Rodgau, Germany

GSK Investigational Site

Schleswig, Germany

GSK Investigational Site

Stuttgart, Germany

GSK Investigational Site

Alexandroupoli, Greece

GSK Investigational Site

Athens, Greece

GSK Investigational Site

Athens, Greece

GSK Investigational Site

Ioannina, Greece

GSK Investigational Site

Rio Patras, Greece

GSK Investigational Site

Thessaloniki, Greece

GSK Investigational Site

Budapest, Hungary

GSK Investigational Site

Budapest, Hungary

GSK Investigational Site

Debrecen, Hungary

GSK Investigational Site

Debrecen, Hungary

GSK Investigational Site

Gyula, Hungary

GSK Investigational Site

Hajdúnánás, Hungary

GSK Investigational Site

Hatvan, Hungary

GSK Investigational Site

Pécs, Hungary

GSK Investigational Site

Siófok, Hungary

GSK Investigational Site

Törökbálint, Hungary

GSK Investigational Site

Zalaegerszeg, Hungary

GSK Investigational Site

Ahmedabad, India

GSK Investigational Site

Hyderabad, India

GSK Investigational Site

Hyderabad, India

GSK Investigational Site

Jaipur, India

GSK Investigational Site

Kanpur, India

GSK Investigational Site

Lucknow, India

GSK Investigational Site

Nagpur, India

GSK Investigational Site

Nagpur, India

GSK Investigational Site

New Delhi, India

GSK Investigational Site

Drogheda, Ireland

GSK Investigational Site

Dublin, Ireland

GSK Investigational Site

Dublin, Ireland

GSK Investigational Site

Galway, Ireland

GSK Investigational Site

Limerick, Ireland

GSK Investigational Site

Ashkelon, Israel

GSK Investigational Site

Beer-Yaakov, Israel

GSK Investigational Site

Haifa, Israel

GSK Investigational Site

Holon, Israel

GSK Investigational Site

Jerusalem, Israel

GSK Investigational Site

Jerusalem, Israel

GSK Investigational Site

Kfar Saba, Israel

GSK Investigational Site

Petah Tikva, Israel

GSK Investigational Site

Ramat Gan, Israel

GSK Investigational Site

Rehovot, Israel

GSK Investigational Site

Bari, Italy

GSK Investigational Site

Ferrara, Italy

GSK Investigational Site

Roma, Italy

GSK Investigational Site

Telese Terme BN, Italy

GSK Investigational Site

Verona, Italy

GSK Investigational Site

Guadalajara, Mexico

GSK Investigational Site

Guadalajara, Mexico

GSK Investigational Site

Jalisco, Mexico

GSK Investigational Site

Monterrey, Mexico

GSK Investigational Site

Monterrey, Mexico

GSK Investigational Site

Breda, Netherlands

GSK Investigational Site

Groningen, Netherlands

GSK Investigational Site

Heerlen, Netherlands

GSK Investigational Site

Rotterdam, Netherlands

GSK Investigational Site

The Hague, Netherlands

GSK Investigational Site

Zutphen, Netherlands

GSK Investigational Site

Havelock North, Hawke's Bay Region, New Zealand

GSK Investigational Site

Auckland, New Zealand

GSK Investigational Site

Hamilton, New Zealand

GSK Investigational Site

Rotorua, New Zealand

GSK Investigational Site

Wellington, New Zealand

GSK Investigational Site

Bialystok, Poland

GSK Investigational Site

Bydgoszcz, Poland

GSK Investigational Site

Częstochowa, Poland

GSK Investigational Site

Elblag, Poland

GSK Investigational Site

Gdansk, Poland

GSK Investigational Site

Gdynia, Poland

GSK Investigational Site

Katowice, Poland

GSK Investigational Site

Katowice, Poland

GSK Investigational Site

Kielce, Poland

GSK Investigational Site

Krakow, Poland

GSK Investigational Site

Krakow, Poland

GSK Investigational Site

Lodz, Poland

GSK Investigational Site

Lodz, Poland

GSK Investigational Site

Ostrowiec Świętokrzyski, Poland

GSK Investigational Site

Poznan, Poland

GSK Investigational Site

Poznan, Poland

GSK Investigational Site

Rzeszów, Poland

GSK Investigational Site

Rzeszów, Poland

GSK Investigational Site

Sopot, Poland

GSK Investigational Site

Sosnowiec, Poland

GSK Investigational Site

Warsaw, Poland

GSK Investigational Site

Warsaw, Poland

GSK Investigational Site

Wroclaw, Poland

GSK Investigational Site

Zamość, Poland

GSK Investigational Site

Daegu, South Korea

GSK Investigational Site

Incheon, South Korea

GSK Investigational Site

Incheon, South Korea

GSK Investigational Site

Jeonju, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Alzira, Spain

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

Benalmádena, Spain

GSK Investigational Site

Cadiz, Spain

GSK Investigational Site

Cáceres, Spain

GSK Investigational Site

Galdakano, Spain

GSK Investigational Site

Granada, Spain

GSK Investigational Site

Granada, Spain

GSK Investigational Site

HebrOn, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Marbella, Spain

GSK Investigational Site

Pozuelo de AlarcOn Madr, Spain

GSK Investigational Site

Santiago de Compostela, Spain

GSK Investigational Site

Valencia, Spain

GSK Investigational Site

Zaragoza, Spain

GSK Investigational Site

Härnösand, Sweden

GSK Investigational Site

Malmö, Sweden

GSK Investigational Site

Uppsala, Sweden

GSK Investigational Site

Taichung, Taiwan

GSK Investigational Site

Taipei, Taiwan

GSK Investigational Site

Birmingham, United Kingdom

GSK Investigational Site

Cardiff, United Kingdom

GSK Investigational Site

Glasgow, United Kingdom

GSK Investigational Site

Hardwick, United Kingdom

GSK Investigational Site

Hexham, United Kingdom

GSK Investigational Site

Lancashire, United Kingdom

GSK Investigational Site

Liverpool, United Kingdom

GSK Investigational Site

London, United Kingdom

GSK Investigational Site

Manchester, United Kingdom

GSK Investigational Site

Norwich, United Kingdom

GSK Investigational Site

Reading, United Kingdom

GSK Investigational Site

Wishaw, United Kingdom

Clinical Research Directory

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (339)